Press Mentions

Bora Pharmaceuticals Wins World Finance Sustainability Award 2025 (1)
Events

Bora Pharmaceuticals Wins World Finance Sustainability Award 2025

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

Bora Pharmaceuticals Wins World Finance Sustainability Award 2025
Business

Bora Adds Automated Fill/Finish Line in Baltimore

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

1
People

Bora Appoints Industry Veteran As Chief Commercial Officer

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

news1_Bora Health_May 23, 2025_1532x510
Community

Bora Health Partners with National Taiwan University Hospital andPatient Groups to Raise Awareness on World Parkinson’s Day

April 11 is World Parkinson’s Day. To mark the occasion,

news2_leadership-awards-r350iam89rm3lfwm14s61h434uls40jd5wqu63d97w
Business

Bora Wins Prestigious CDMO Leadership Awards

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

news3_Tanvex BioPharma_January 20, 2025_1532x510
Business

Tanvex BioPharma Completes Acquisition of Bora Biologics, Launching New Era in Biologics Development

Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization

news4_Bora Company_January 17, 2025_1532x510
Events, Investors

Bora Company Presentation at 43rd Annual J.P. Morgan Healthcare Conference

43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been

news5_Bora Biologics_Nov 1, 2024_1532x510
Business

Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer

Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development

news6_Bora Pharmaceuticals_January 6, 2025_1532x510
Business

Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan 

Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site

news8_Bora Pharmaceuticals_October 25, 2024_1523x600
Business

Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

news9_Bora Appoints_October 3, 2024_1523x510
People

Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472),

2
People

Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business

Bora Appoints J.D. Mowery As First Division President Of Its

You're leaving our site

You are being redirected to BoraBiologics.com